degradation reported above 25 C
Commonly Reported Side Effects Mild injection site irritation or redness Headache or fatigue (usually transient in early dosing) Nausea (rare, typically with higher doses or fasted use) In human trials, AOD9604 demonstrated a strong safety profile with no significant adverse effects or changes in glucose, insulin, or organ size. Heffernan et al., Journal of Endocrinology No IGF-1 Elevation or Growth Risks Unlike hGH, AOD9604 does not stimulate systemic growth meaning: No risk of acromegaly or organ hypertrophy No increase in cancer risk tied to IGF-1 elevation No suppression of natural hormone production Not a Controlled Substance AOD9604 is not scheduled or classified as a controlled substance in the U.S

A seminal cost analysis published in Canadian Family Physician (2001) projected that switching patients from intramuscular B12 injections to oral supplements could save between $2.9 million and $17.6 million depending on the population studied with one Ontario analysis estimating $14.5 million in savings for 110,000 elderly patients
Retrieved from Rise Mens Health
Older adults, especially in isolation and those with cognitive decline/dementia, may become more anxious, angry, stressed, agitated and withdrawn during the outbreak or while in quarantine
CPT code 78452 is a nuclear medicine procedure used for myocardial perfusion imaging (MPI)